Plain-English translation of NCT03570749 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alopecia areata research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial studied whether a medication called could help people with severe alopecia areata (a condition that causes significant hair loss) regrow their hair. Researchers tested different doses of the medication against a placebo to find out which dose worked best and was safest. The trial included hundreds of participants and lasted nearly 4 years.
Alopecia areata is a condition where the immune system attacks hair follicles, causing sudden and sometimes severe hair loss that can deeply affect a person's quality of life. This medication was being studied because it works by calming down the immune system, which researchers hoped could help stop hair loss and promote regrowth.
Participants took a daily tablet by mouth, either containing the medication being tested or a placebo, along with additional tablets to keep the study blinded so they wouldn't know which they were receiving. The trial involved check-in visits where researchers measured hair regrowth using a standardized tool and monitored for any side effects. Treatment continued for up to 200 weeks, with some participants receiving rescue therapy if they weren't improving.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States